🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

DR AGARWALS HEALTH CARE L AGARWALEYE NSEPHARMA

Healthcare · Medical Instruments & Supplies · India
https://www.dragarwals.co.in
Company Profile ↓
₹491.85
+12.59% 1Y
Mkt Cap₹15,582.18 Cr
P/E176.92
P/B7.81
52W High₹545.70
52W Low₹406.55
Book Value₹63.93
EPS (TTM)₹2.78

Company Overview

Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 12.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 27.0% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,080.08 Cr (+21.6% YoY); net profit ₹133.19 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +21.6%, earnings +59.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 27.0%, profit CAGR 12.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:26.96%
1 Year:21.57%

Compounded Profit Growth

5 Years:12.28%
1 Year:59.59%

Stock Price Performance

1 Year:+12.59%
6 Months:-4.17%
3 Months:+10.17%
1 Month:+11.96%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 61% of range
₹406.55 ₹545.70
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)60.98 · Neutral
Price Performance
1M+11.96%
3M+10.17%
6M-4.17%
1Y+12.59%
Valuation vs Sector

P/E of 176.92 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 27.0% over 5 years.
  • Profit CAGR of 12.3% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 176.9.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
176.92
Industry PE
39.97
Forward P/E
59.36
PEG Ratio
-
Book Value
₹63.93
Price to Book
7.81
P/S
7.59
EV/EBITDA
28.40
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
26.96%
Profit 5Y
12.28%
Revenue (YoY)
21.57%
Earnings (YoY)
59.59%

Profitability & Returns

ROCE
9.74%
ROE
6.58%
ROA
3.38%
Profit Margin
6.40%
Op Margin
14.10%
Gross Margin
63.85%
EPS (Latest Qtr)
₹1.24
EPS (TTM)
₹2.78

Balance Sheet & Liquidity

Debt/Equity
0.53
Quick Ratio
1.04
Current Ratio
1.24
Debt
₹1,066.20 Cr
Total Assets
₹3,941.75 Cr
Current Assets
₹572.97 Cr
Working Capital
₹111.49 Cr

Ownership

Promoter Holding
75.47%
Chg in Prom Hold
-0.01%
FII / Inst Holding
19.30%
Chg in FII Hold
-0.17%

Financial Snapshot

Enterprise Value
₹15,582.18 Cr
Total Revenue (TTM)
₹2,080.08 Cr
EBITDA
₹615.34 Cr
Free Cash Flow
₹58.41 Cr
Operating Cash Flow
₹518.99 Cr
Shares Outstanding
₹31.68 Cr
Gross Margin
63.85%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AGARWALEYE DR AGARWALS HEALTH CARE L NSEPHARMA 491.85 176.92 ₹15,582.18 Cr 0.00% 9.74% 6.58% 26.96% 12.28%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 333.00 Cr349.00 Cr403.00 Cr417.00 Cr430.72 Cr460.22 Cr487.42 Cr-529.86 Cr564.11 Cr
Cost of Revenue -----167.35 Cr179.96 Cr178.45 Cr196.72 Cr196.76 Cr
Gross Profit -----292.87 Cr307.46 Cr320.24 Cr333.14 Cr367.35 Cr
Operating Expenses 244.00 Cr241.00 Cr300.00 Cr310.00 Cr-222.27 Cr242.55 Cr251.96 Cr257.79 Cr282.56 Cr
Operating Income 46.00 Cr61.00 Cr48.00 Cr50.00 Cr56.63 Cr70.60 Cr64.91 Cr-75.35 Cr84.79 Cr
EBITDA 89.00 Cr108.00 Cr104.00 Cr107.00 Cr127.52 Cr143.92 Cr141.25 Cr-154.64 Cr175.38 Cr
Interest Expense 22.00 Cr27.00 Cr27.00 Cr28.00 Cr28.35 Cr25.01 Cr24.70 Cr-21.13 Cr22.08 Cr
Pretax Income 36.00 Cr54.00 Cr27.00 Cr33.00 Cr40.99 Cr58.52 Cr53.60 Cr-64.76 Cr76.62 Cr
Tax Provision 13.32 Cr12.96 Cr8.91 Cr11.88 Cr12.75 Cr15.97 Cr15.54 Cr-21.13 Cr26.66 Cr
Net Income 23.00 Cr41.00 Cr18.00 Cr21.00 Cr22.34 Cr32.57 Cr30.05 Cr-33.74 Cr39.71 Cr
Diluted EPS ----0.711.030.95-1.061.24

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 531.00 Cr471.00 Cr-1,016.48 Cr1,327.67 Cr1,711.00 Cr2,080.08 Cr
Cost of Revenue ---558.55 Cr728.57 Cr635.37 Cr751.89 Cr
Gross Profit ---457.93 Cr599.10 Cr1,075.63 Cr1,328.19 Cr
Operating Expenses 407.00 Cr387.00 Cr-304.38 Cr397.25 Cr849.99 Cr1,034.86 Cr
Operating Income 31.00 Cr-10.00 Cr-153.55 Cr201.85 Cr225.64 Cr293.33 Cr
EBITDA 124.00 Cr85.00 Cr-283.86 Cr406.56 Cr499.38 Cr615.34 Cr
Interest Expense 54.00 Cr44.00 Cr-71.97 Cr95.62 Cr108.79 Cr90.46 Cr
Pretax Income -11.00 Cr-48.00 Cr-83.59 Cr140.57 Cr159.85 Cr248.64 Cr
Tax Provision -9.02 Cr-10.08 Cr--19.64 Cr45.52 Cr49.51 Cr80.50 Cr
Net Income -21.00 Cr-59.00 Cr-94.10 Cr83.06 Cr83.46 Cr133.19 Cr
Diluted EPS --1.192.982.632.78-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 751.00 Cr787.00 Cr-1,825.17 Cr2,752.82 Cr3,671.57 Cr3,941.75 Cr
Current Assets ---310.18 Cr758.58 Cr794.07 Cr572.97 Cr
Cash & Equivalents ---126.98 Cr111.75 Cr103.61 Cr90.55 Cr
Inventory ---36.04 Cr51.90 Cr80.27 Cr94.03 Cr
Receivables ---76.33 Cr96.81 Cr123.56 Cr160.91 Cr
Total Liabilities ---1,166.10 Cr1,373.31 Cr1,744.75 Cr1,822.05 Cr
Current Liabilities ---301.31 Cr399.80 Cr477.76 Cr461.48 Cr
Long Term Debt ---305.60 Cr309.62 Cr157.29 Cr133.30 Cr
Total Debt 162.00 Cr185.00 Cr-857.35 Cr966.44 Cr960.91 Cr1,066.20 Cr
Total Equity 249.00 Cr184.00 Cr-629.56 Cr1,339.41 Cr1,866.59 Cr2,025.46 Cr
Shares Outstanding ---31.59 Cr31.59 Cr31.59 Cr31.68 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 103.00 Cr99.00 Cr-233.11 Cr346.00 Cr357.13 Cr518.99 Cr
Investing Cash Flow -85.00 Cr-46.00 Cr--509.08 Cr-913.91 Cr-750.33 Cr-308.45 Cr
Financing Cash Flow -73.00 Cr-37.00 Cr-303.34 Cr552.68 Cr381.85 Cr-220.39 Cr
Capital Expenditure -201.00 Cr-33.00 Cr--157.80 Cr-232.33 Cr-320.90 Cr-460.58 Cr
Free Cash Flow -98.00 Cr66.00 Cr-75.31 Cr113.67 Cr36.23 Cr58.41 Cr
Net Change in Cash -56.00 Cr17.00 Cr-27.36 Cr-15.23 Cr-11.35 Cr-9.85 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---45.1%45.1%62.9%63.9%
Operating Margin % 5.8%-2.1%-15.1%15.2%13.2%14.1%
Net Margin % -4.0%-12.5%-9.3%6.3%4.9%6.4%
ROE % -8.4%-32.1%-14.9%6.2%4.5%6.6%
ROCE % ---10.1%8.6%7.1%8.4%

Shareholding Pattern

Insiders
75.47%
Institutions
19.30%
Public Float
78.69%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AGARWALEYE

Google News Fri, 22 May 2026

AGARWALEYE Stock Price and Chart — NSE:AGARWALEYE - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE44WjdDbVdxRXlzNVpsazhhd01Cbk1zTnJaeV8xVEIyMEVzeEtGWkMtd2lDZWJiT295RGpDZFFodlJoMVJPM3BMWFR1a1JOMjJRTjItNzIwZ3k3X3V5U1ZOUw?oc=5" target="_blank">AGARWALEYE Stock Price and Chart — NS…

Google News Sun, 24 May 2026

Here's What Analysts Are Forecasting For Dr. Agarwal's Health Care Limited (NSE:AGARWALEYE) After Its Yearly Results - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPRkNBMlZvU0YyUWc3SEQtbGtrRXNlU01GM0tVajU4aEJmZ2o0QVFiSU5pYXlpRHZ6OEtqZUVlMXpEZEFoN1k3VVoyQWFHaFN0X25aVnhXUlZ2cWpxWF9WRTVJa1FSalFMeVN1RFluc1lPZXlNbkpxaElyVEhWWmM5czlCS3N5Tk5wSzF3dk…

Google News Fri, 06 Feb 2026

Dr. Agarwal's Health Care Limited's (NSE:AGARWALEYE) Share Price Not Quite Adding Up - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQTHZkX2dmUjROcktuWGthbTFMNnVrQ3ZDSENrVll4emJNWGVnMnBVMkVOdkk2eURLZXpCTU13UjlYZVNKaHgyQlJfT0hnMkI0VTdVQUFfUmE2TTQ1MDBQUGhENXc5dVVuc0NVQzdmLUQ1cWtRWFdQeHJMTC1ZQWhydGJXWkk1LUVzSWtNRF…

Google News hu, 28 Aug 2025

Dr Agarwal's Eye Hospital stock sinks 18% as board approves merger with Dr Agarwal's Healthcare - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxQQXFLYmx0ZjFjaGFVdzA5NkZwcDdOU3dsUW55MS1mNW0tWVdmOWNGOFA5eTRxMmRZR1Z1Yk9pcVkzbEoxQ1VNYU9oTlM0N0Q0Wmt2ckhwbWFMT1NWN3pxMExGTjNwd3UwSjNNOXc0NjF5el80eFY4TUFJdXQ1eE54Q1dMN3g3cDc3TlNZZk…

Google News ue, 05 May 2026

DR AGARWALS HEALTH CARE L Share Price - Live NSE: AGARWALEYE Stock Price & Chart - Upstox

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE4zSVZrQUFjWXdhWjdGNmxDQW1uVUpJS1RyOVlUc0VXVk53TjVIWU01dGQ0dXBzb0E3UURoYlR0RmdGNnlZcGdnejlyUXJYc0lSVm5vdldqS1Z3cTg4ZkJPT0VGVE1pVjR4ODUtRkVwOW5GZw?oc=5" target="_blank">DR AGARWALS H…

Google News hu, 28 Aug 2025

Dr Agarwal's Health Care, Eye Hospital shares tumble up to 17%; here's why - Business Standard

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOanJybVNqRTBJMzItdUsyUUh6azNOWTEtQnVsanNYemhwa0NJaDI5eXFvTGxwSndPeHN3aDIyTE1oWks4UnA5bWtNcWd1TW1jY0Y1YzV5b2ZHMzFKTmpyMUIzemR4WXI3a2NOaktfTmpYSlZCQWtRc1h0amJLY0UyNldITmRCNWpPS1ZES3…

AGARWALEYE — Frequently Asked Questions

What is the current share price of DR AGARWALS HEALTH CARE L (AGARWALEYE)?

As of 2026-07-15 09:52 IST, DR AGARWALS HEALTH CARE L (AGARWALEYE) trades at ₹491.85 on NSE. Its 52-week range is ₹406.55 to ₹545.70.

What is the market capitalisation of AGARWALEYE?

DR AGARWALS HEALTH CARE L (AGARWALEYE) has a market capitalisation of ₹15,582.18 Cr on NSE.

What is the P/E ratio of AGARWALEYE?

AGARWALEYE trades at a trailing price-to-earnings (P/E) ratio of 176.92. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 7.81.

What is the return on equity (ROE) of AGARWALEYE?

AGARWALEYE has a return on equity (ROE) of 6.58%. Its return on capital employed (ROCE) is 9.74%.

Is AGARWALEYE a good stock to buy?

This page provides a data-driven analysis of DR AGARWALS HEALTH CARE L (AGARWALEYE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space